

Marlana Orloff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2136187/publications.pdf>

Version: 2024-02-01

21
papers

920
citations

840585

11
h-index

752573

20
g-index

21
all docs

21
docs citations

21
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	13.9	376
2	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
3	PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. <i>Immunotherapy</i> , 2017, 9, 1323-1330.	1.0	64
4	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	49
5	Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 405.	1.7	28
6	An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. <i>Cancers</i> , 2020, 12, 117.	1.7	25
7	Genetic Landscape and Emerging Therapies in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5503.	1.7	17
8	Melanoma Immunotherapy in the Elderly. <i>Current Oncology Reports</i> , 2018, 20, 20.	1.8	16
9	Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. <i>Ophthalmology</i> , 2022, 129, 679-693.	2.5	16
10	Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. <i>Oncolytic Virotherapy</i> , 2016, Volume 5, 91-98.	6.0	13
11	Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 81-86.	0.4	12
12	Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5749.	1.7	10
13	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9509-9509.	0.8	7
14	Pemphigus associated with ipilimumab therapy. <i>International Journal of Dermatology</i> , 2021, 60, e331-e333.	0.5	6
15	Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9526-9526.	0.8	6
16	Treatment of Metastatic Melanoma in the Elderly. <i>Current Oncology Reports</i> , 2022, 24, 825-833.	1.8	5
17	Successes and setbacks of early investigational drugs for melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 993-997.	1.9	4
18	Unique Geospatial Accumulations of Uveal Melanoma. <i>American Journal of Ophthalmology</i> , 2020, 220, 102-109.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Controlling Conjunctival Melanomaâ€”To Infinity and Beyond. JAMA Ophthalmology, 2020, 138, 608.	1.4	4
20	Review of bi-specific therapies in uveal melanoma. Cancer Gene Therapy, 2022, 29, 1814-1818.	2.2	4
21	Abstract 3295: Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma. , 2020, , .		2